Delphin N, Aust C, Griffiths L, Fernandez F
Genes (Basel). 2024; 15(3).
PMID: 38540331
PMC: 10970389.
DOI: 10.3390/genes15030272.
Romer T, Jeppesen R, Christensen R, Benros M
Mol Psychiatry. 2023; 28(6):2277-2290.
PMID: 37169812
DOI: 10.1038/s41380-023-02059-2.
Ueno F, Iwata Y, Nakajima S, Caravaggio F, Rubio J, Horga G
Neurosci Biobehav Rev. 2021; 132:1205-1213.
PMID: 34718049
PMC: 9059704.
DOI: 10.1016/j.neubiorev.2021.10.028.
McCutcheon R, Krystal J, Howes O
World Psychiatry. 2020; 19(1):15-33.
PMID: 31922684
PMC: 6953551.
DOI: 10.1002/wps.20693.
Bortz D, Grace A
NPJ Schizophr. 2018; 4(1):17.
PMID: 30177811
PMC: 6120917.
DOI: 10.1038/s41537-018-0059-3.
Presynaptic dopaminergic function: implications for understanding treatment response in psychosis.
Bonoldi I, Howes O
CNS Drugs. 2014; 28(7):649-63.
PMID: 24919790
DOI: 10.1007/s40263-014-0177-z.
The fallacy of the medical model and the dangers of psychotropic drugs as a mode of treatment for mental disorders.
Sanua V
J Prim Prev. 2013; 17(1):149-73.
PMID: 24254926
DOI: 10.1007/BF02262743.
Schizophrenia-like features in transgenic mice overexpressing human HO-1 in the astrocytic compartment.
Song W, Zukor H, Lin S, Hascalovici J, Liberman A, Tavitian A
J Neurosci. 2012; 32(32):10841-53.
PMID: 22875919
PMC: 6621004.
DOI: 10.1523/JNEUROSCI.6469-11.2012.
Dopamine system dysregulation by the hippocampus: implications for the pathophysiology and treatment of schizophrenia.
Grace A
Neuropharmacology. 2011; 62(3):1342-8.
PMID: 21621548
PMC: 3179528.
DOI: 10.1016/j.neuropharm.2011.05.011.
Dopamine system dysregulation by the ventral subiculum as the common pathophysiological basis for schizophrenia psychosis, psychostimulant abuse, and stress.
Grace A
Neurotox Res. 2010; 18(3-4):367-76.
PMID: 20143199
PMC: 2932888.
DOI: 10.1007/s12640-010-9154-6.
The role of serotonin in schizophrenia: an overview of the nomenclature, distribution and alterations of serotonin receptors in the central nervous system.
Ohuoha D, Hyde T, Kleinman J
Psychopharmacology (Berl). 1993; 112(1 Suppl):S5-15.
PMID: 7831440
DOI: 10.1007/BF02245003.
Partial improvement in negative schizophrenic symptoms after amphetamine.
Angrist B, Peselow E, Rubinstein M, Corwin J, Rotrosen J
Psychopharmacology (Berl). 1982; 78(2):128-30.
PMID: 6817367
DOI: 10.1007/BF00432248.
Psychotherapeutic drugs and biogenic amines. Current concepts and therapeutic implications.
Potter W
Drugs. 1984; 28(2):127-43.
PMID: 6205841
DOI: 10.2165/00003495-198428020-00003.
The biology of schizophrenia.
Crow T
Experientia. 1982; 38(11):1275-82.
PMID: 6129159
DOI: 10.1007/BF01954914.
Responses to apomorphine, amphetamine, and neuroleptics in schizophrenic subjects.
Angrist B, Rotrosen J, Gershon S
Psychopharmacology (Berl). 1980; 67(1):31-8.
PMID: 6102776
DOI: 10.1007/BF00427592.
Molecular pathology of schizophrenia: more than one disease process?.
Crow T
Br Med J. 1980; 280(6207):66-8.
PMID: 6101544
PMC: 1600263.
DOI: 10.1136/bmj.280.6207.66.
3H-spiperone binding sites in post-mortem brains from schizophrenic patients: relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms.
Kornhuber J, Riederer P, Reynolds G, Beckmann H, Jellinger K, Gabriel E
J Neural Transm. 1989; 75(1):1-10.
PMID: 2563750
DOI: 10.1007/BF01250639.
Determination of 3-methoxy-4-hydroxyphenylglycol conjugates in urine. Application to the study of central noradrenaline metabolism in unmedicated chronic schizophrenic patients.
Joseph M, Baker H, Johnstone E, Crow T
Psychopharmacology (Berl). 1976; 51(1):47-51.
PMID: 827775
DOI: 10.1007/BF00426320.
Endogenous ligands of a putative LSD-serotonin receptor in the cerebrospinal fluid: higher level of LSD-displacing factors (LDF) in unmedicated psychotic patients.
MEHL E, Ruther E, Redemann J
Psychopharmacology (Berl). 1977; 54(1):9-16.
PMID: 410064
DOI: 10.1007/BF00426533.
Dopaminergic mechanisms and cognitive deficit in schizophrenia. A neurobiological model.
Joseph M, Frith C, Waddington J
Psychopharmacology (Berl). 1979; 63(3):273-80.
PMID: 113814
DOI: 10.1007/BF00433561.